LONDON, May 12, 2014 /PRNewswire/ --
The US markets saw a positive sentiment on Friday, May 9, 2014, with the NASDAQ Composite closing at 4,071.87, up 0.50%, the Dow Jones Industrial Average ending the session 0.20% higher at 16,583.34, and the S&P 500 edging 0.15% higher to finish the trading session at 1,878.48. The gains were broad based as six out of the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 668.35, up 0.58%, with the index advancing 3.66% in the last one month. Investor-Edge has initiated coverage on the following equities: Salix Pharmaceuticals Ltd (NASDAQ: SLXP), Nektar Therapeutics (NASDAQ: NKTR), Corcept Therapeutics Inc. (NASDAQ: CORT) and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free technical research on SLXP, NKTR, CORT and JAZZ can be downloaded upon signing up at:
Shares in Salix Pharmaceuticals Ltd finished the Friday's session 2.13% lower at $103.56. A total of 1.45 million shares were traded, which was above its three months average volume of 1.11 million shares. The stock vacillated between $100.52 and $105.53 during the session. Over the last one month and the previous three months, Salix Pharmaceuticals Ltd's shares have advanced 4.53% and 1.16%, respectively. Additionally, from the beginning of 2014, the company's stock has gained an upside of 15.14%. The stock is trading above its 200-day moving average of $87.76, while the 200-day moving average is below Salix Pharmaceuticals Ltd's 50-day moving average of $107.34. The company's stock traded at a PE ratio of 50.99 and has a Relative Strength Index (RSI) of 42.56. Sign up today to read free research on SLXP at:
On Friday, shares in Nektar Therapeutics fluctuated between $10.53 and $11.00 before ending the session 0.46% higher at $10.93. The stock reported a trading volume of 1.06 million shares, below its three months average volume of 1.28 million shares. Nektar Therapeutics's shares have advanced 3.80% in the last one month, whereas the stock has fallen by 2.50% in the previous three trading sessions and 3.70% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $12.29 and $11.95, respectively. Moreover, shares of Nektar Therapeutics have an RSI of 41.69. Sign up today to read free research on NKTR at:
On Friday, shares in Corcept Therapeutics Inc. surged 5.75%, to close the day at $1.84. The stock recorded a trading volume of 1.58 million shares, much above its three months average volume of 0.67 million shares. The stock oscillated between $1.69 and $1.93 during the session. Over the last three trading sessions and over the past one month, Corcept Therapeutics Inc.'s shares have plummeted 54.23% and 49.31%, respectively. Further, the stock has declined 42.68% since the start of this year. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $3.84 is greater than its 200-day moving average of $2.65. Additionally, Corcept Therapeutics Inc.'s stock has an RSI of 27.77. Sign up today to read free research on CORT at:
On Friday, shares in Jazz Pharmaceuticals PLC recorded a trading volume of 3.02 million shares, higher than its three months average volume of 1.23 million shares. The stock ended the day at $129.45, which was 3.17% below its previous day's closing of $133.69, and registered an intraday range of $120.38 and $129.76. Shares of the company traded at a PE ratio of 73.10. Although Jazz Pharmaceuticals PLC's stock has lost 5.99% in the previous three trading sessions, it has advanced 0.65% in the last one month and 2.28% on YTD basis. The company's stock is trading above its 200-day moving average of $117.69. Furthermore, shares of Jazz Pharmaceuticals PLC have an RSI of 39.36. Sign up today to read free research on JAZZ at:
=============== EDITOR'S NOTES: ===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.